<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-115028</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Diabetes and osteoporosis: action of gastrointestinal hormones on the bone</dc:title>
<dc:description xml:lang="en">A 62-year-old woman consulted for evaluation of treatment for her type 2 diabetes diagnosed four years ago. He had been received treatment with metformin 850mg twice, with no chronic associated complications. She had hypertension and dyslipidemia. She was being treated with candesartan/hydrochlorothiazide 32/12.5mg and atorvastatin 40mg. Her weight was 92kg and height 162cm (BMI, 35.1kg/m2). The last analysis showed fasting glucose 168mg/dl and glycated hemoglobin 7.5%, Microalbuminuria was negative. Blood pressure and lipid profile were within the therapeutic range. Two years ago she suffered a nontraumatic Colle's fracture in her left arm for which she was taking a daily calcium and vitamin D supplement and weekly alendronate. In summary, this is an obese female patient with type 2 diabetes mellitus and inadequate metabolic control, She also has a history of fragility fracture. How should this patient be evaluated and treated?(AU)</dc:description>
<dc:creator>García-Martín, A</dc:creator>
<dc:creator>Reyes-García, R</dc:creator>
<dc:creator>Muñoz-Torres, M</dc:creator>
<dc:creator>García-Castro, J. M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Mujer de 62 años, que consulta para valoración de tratamiento de diabetes mellitus tipo 2 (DM2) de 4 años de evolución, en tratamiento con metformina 850mg/12h, sin complicaciones crónicas asociadas. Presenta hipertensión y dislipemia. Tratada con candesartán/hidroclorotiazida 32/12,5mg/día y atorvastatina 40mg/día. Pesaba 92kg y medía 162cm (IMC:35,1kg/m2). En el último control analítico, glucemia basal 168mg/dl y HbA1c 7,5%. La microalbuminuria era negativa. Las cifras de presión arterial y el perfil lipídico se encontraban dentro de los objetivos terapéuticos. Hace 2 años tuvo una fractura de Colles no traumática en la muñeca izquierda motivo por el que toma un suplemento de calcio y vitamina D diariamente y bifosfonato alendronato una vez por semana. En resumen, nos encontramos ante una mujer con obesidad y DM2, con un control metabólico inadecuado, que además presenta antecedentes de fractura por fragilidad. ¿Cómo debe ser evaluada y tratada esta paciente?(AU)</dc:description>
<dc:source>Rev Clin Esp;213(6): 293-197, ago.-sept.2013.</dc:source>
<dc:identifier>ibc-115028</dc:identifier>
<dc:title xml:lang="es">Diabetes y osteoporosis: acción de las hormonas gastrointestinales sobre el hueso</dc:title>
<dc:subject>^d3946^s22057</dc:subject>
<dc:subject>^d3946^s22012</dc:subject>
<dc:subject>^d10205^s22012</dc:subject>
<dc:subject>^d5909^s22079</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d52846^s22044</dc:subject>
<dc:subject>^d5909^s22044</dc:subject>
<dc:subject>^d10205^s22016</dc:subject>
<dc:subject>^d52846^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7152^s22012</dc:subject>
<dc:subject>^d7005^s22073</dc:subject>
<dc:subject>^d7130^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d5909^s22073</dc:subject>
<dc:subject>^d7130^s22012</dc:subject>
<dc:subject>^d8862^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d3946^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>201309</dc:date>
</metadata>
</record>
</ibecs-document>
